Drug Trial Radar · NCT04702880
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Mar 17, 2021
Primary completion
May 22, 2025
Study completion Nov 28, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
Conditions
- Extensive-stage Small Cell Lung Cancer
Interventions
BMS-986012Biological
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
EtoposideDrug
Specified dose on specified days
NivolumabBiological
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
- Number of Participants With Serious Adverse EventsTime frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
- Number of Participants With Adverse Events Leading to DiscontinuationTime frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
- Number of Participants Who DiedTime frame: From first dose to primary cutoff date (Up to approximately 43 months)
- Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)Time frame: From randomization to the date of the first documented tumor progression, or death, or primary cutoff date, whichever occurs first (Up to approximately 50 months)
Locations
39 sites in 11 countries. Site status is shown where the registry gives one.
Local Institution - 0075
Birmingham, Alabama
Local Institution - 0022
Hackensack, New Jersey
Local Institution - 0002
Durham, North Carolina
Local Institution - 0060
Cincinnati, Ohio
Local Institution
Cincinnati, Ohio
Local Institution - 0067
Cleveland, Ohio
Local Institution - 0081
Nashville, Tennessee
Local Institution
Dallas, Texas
Local Institution - 0003
Westmead, New South Wales, Australia
Local Institution - 0023
Greenslopes, Queensland, Australia
Local Institution - 0001
Malvern, Victoria, Australia
Local Institution - 0004
Murdoch, Western Australia, Australia
Local Institution - 0034
Ghent, Belgium
Local Institution - 0050
Liège, Belgium
Local Institution - 0051
Charleroi, Hainaut, Belgium
Local Institution - 0012
Edmonton, Alberta, Canada
Local Institution - 0064
Brampton, Ontario, Canada
Local Institution - 0036
Athens, Greece
Local Institution - 0038
Athens, Greece
Local Institution - 0045
Heraklion, Irakleío, Greece
Local Institution - 0030
Peschiera del Garda, Italy
Local Institution - 0031
Pisa, Italy
Local Institution - 0029
Rozzano, Italy
Local Institution - 0073
Sendai, Miyagi, Japan
Local Institution - 0070
Ōsaka-sayama, Osaka, Japan
Local Institution - 0069
Takatsuki, Osaka, Japan
Local Institution - 0077
Ina-machi, Saitama, Japan
Local Institution - 0066
Arnhem, Netherlands
Local Institution - 0040
Groningen, Netherlands
Local Institution - 0039
Amsterdam, North Holland, Netherlands
Local Institution - 0049
Gdansk, Poland
Local Institution - 0048
Lodz, Poland
Local Institution - 0043
Bucharest, Romania
Local Institution - 0042
Cluj-Napoca, Romania
Local Institution - 0041
Craiova, Romania
Local Institution - 0021
Madrid, Spain
Local Institution - 0005
Majadahonda, Spain
Local Institution - 0006
Málaga, Spain
Local Institution - 0007
Barcelona, Barcelona [Barcelona], Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.